Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sarilumab on Atherosclerotic Disease in Rheumatoid Arthritis
2019-004078-24Phase 4Active
- Sponsor
- IDIVAL
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sarilumab in rheumatoid arthritis (RA), sponsored by IDIVAL. Primary endpoint: Effect on carotid atheroma plaque inflammation and mineralization. Started Feb 2020; status: active.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-004078-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004078-24.